Background: Magnetic resonance imaging may improve the staging of prostate cancer compared 
with clinical evaluation alone, computerized tomography, or trans-rectal ultrasound, and it allows 
simultaneous and detailed evaluation of prostatic, periprostatic, and pelvic anatomy. Magnetic 
resonance imaging and magnetic resonance spectroscopic imaging (MRI/MRSI) allow better 
visualization of the zonal anatomy of the prostate and better delineation of tumor location, volume, 
and extent (stage). Metabolic criteria used to identify and localize prostate cancer with MRI/MRSI 
have been standardized, thus improving the accuracy of the examination and limiting inter observer 
variations in interpretation. Objective: The aim of this study is to evaluate the diagnostic efficiency of 
MR spectroscopy in evaluating the prostatic tumors in the form of differentiation of benign from 
malignant prostatic tumors. Patients and methods: This study was conducted on 50 patients with 
prostatic tumors at Radiodiagnosis Department Al-Azhar University, Assiut, during the period from 
October 2015 to March 2018, all patients were subjected to complete history taking, clinical 
examination, laboratory assessment (PSA), trans-rectal ultrasonography, MRI, and prostatic biopsy.
Results: In our study, we proved high sensitivity and specificity of MP-MRI reaching 100% and 
96.67% respectively in the diagnosis of patients with elevated PSA level and hard nodule by DRE.
Conclusion: In our research, we analyzed the combined use of T2-weighted imaging and H-MRS to 
detect prostate cancer accurately. We hypothesized that combined information of non-invasive 
morphologic and functional MR techniques, multiparametric MR imaging approach rather than the use of 
either sequence alone could easily improve the detection, localization, and grading of prostate 
cancers.